Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (17)

2020

  1. Congenital antithrombin deficiency in patients with splanchnic vein thrombosis

    Liver International, Vol. 40, Núm. 5, pp. 1168-1177

2019

  1. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content

    Platelets, Vol. 30, Núm. 6, pp. 743-751

2018

  1. Genetic predisposition to fetal alcohol syndrome: Association with congenital disorders of N-glycosylation

    Pediatric Research, Vol. 83, Núm. 1, pp. 119-127

2017

  1. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1

  2. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

  3. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study

    European Journal of Radiology, Vol. 87, pp. 66-75

2016

  1. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

    Medicina Clinica

2015

  1. Cost-effectiveness of rivaroxaban in the treatment of venous thromboembolism in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 12, Núm. 4, pp. 147-156

  2. Embolia pulmonar en el paciente oncológico: bases para el estudio EPIPHANY

    Medicina Clinica, Vol. 144, Núm. S1, pp. 31-37

2014

  1. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

    Annals of Hematology, Vol. 93, Núm. 12, pp. 2037-2043

  2. Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: Results from a collaborative study

    Orphanet Journal of Rare Diseases, Vol. 9, Núm. 1

2012

  1. Assessment and prognostic value of the European leukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

    Blood, Vol. 119, Núm. 6, pp. 1363-1369

2010

  1. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

    Blood, Vol. 116, Núm. 8, pp. 1205-1210

2006

  1. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients

    Stroke, Vol. 37, Núm. 9, pp. 2288-2293

2003

  1. Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky-Pudlak syndrome: Role of insC974 in platelet function and clinical relevance

    British Journal of Haematology, Vol. 123, Núm. 1, pp. 132-138

1999

  1. Von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi®) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions

    Haematologica, Vol. 84, Núm. 1, pp. 5-11

1993

  1. Absence of effect of DDAVP infusion on platelet glycoprotein ib/IX and IIb/IIIa complexes, and their interaction with newly released von willebrand factor

    Platelets, Vol. 4, Núm. 4, pp. 219-224